On July 24, CMC and Taizhou Edding Jing'ang Pharmaceutical Co., Ltd. held a signing ceremony for a drug R&D and industrialization project. Edding Jing'ang Pharmaceutical will industrialize four national new Category 1 drugs in CMC, all of which have obtained the Clinical Drug Trial Approval.
Taizhou Edding Jing'ang Pharmaceutical focuses on the introduction, clinical R&D, production and sales of new cancer drugs. The company currently owns 5 national innovative Category 1 drugs, and 4 of them have obtained clinical approval. The company ranks among China's top 100 enterprises in terms of comprehensive drug R&D capability in 2018.